SEER Limited-Use cancer incidence data with associated population data. Geographic areas available are county and SEER registry. The Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute collects and distributes high quality, comprehensive cancer data from a number of population-based cancer registries. Data include patient demographics, primary tumor site, morphology, stage at diagnosis, first course of treatment, and follow-up for vital status. The SEER Program is the only comprehensive source of population-based information in the United States that includes stage of cancer at the time of diagnosis and survival rates within each stage.

Users can access data about cancer statistics in the United States including but not limited to searches by type of cancer and race, sex, ethnicity, age at diagnosis, and age at death. Background Surveillance Epidemiology and End Results (SEER) database’s mission is to provide information on cancer statistics to help reduce the burden of disease in the U.S. population. The SEER database is a project to the National Cancer Institute. The SEER database collects information on incidence, prevalence, and survival from specific geographic areas representing 28 percent of the United States population. User functionality Users can access a variety of reso urces. Cancer Stat Fact Sheets allow users to look at summaries of statistics by major cancer type. Cancer Statistic Reviews are available from 1975-2008 in table format. Users are also able to build their own tables and graphs using Fast Stats. The Cancer Query system provides more flexibility and a larger set of cancer statistics than F ast Stats but requires more input from the user. State Cancer Profiles include dynamic maps and graphs enabling the investigation of cancer trends at the county, state, and national levels. SEER research data files and SEER*Stat software are available to download through your Internet connection (SEER*Stat’s client-server mode) or via discs shipped directly to you. A signed data agreement form is required to access the SEER data Data Notes Data is available in different formats depending on which type of data is accessed. Some data is available in table, PDF, and html formats. Detailed information about the data is available under “Data Documentation and Variable Recodes”.

examined regional LNs

Rate: Number of new cases of breast cancer (per 100,000) diagnosed at the regional or distant stage among females.

Definition: Age-adjusted incidence rate of invasive breast cancer per 100,000 female population.

Data Sources:

(1) NJ State Cancer Registry, Dec 31, 2015 Analytic File, using NCI SEER*Stat ver 8.2.1 (www.seer.cancer.gov/seerstat)

(2) NJ population estimates as calculated by the NCI's SEER Program, released January 2015, http://www.seer.cancer.gov/popdata/download.html.

E)Your Dataset This dataset of breast cancer patients was obtained from the 2017 November update of the SEER Program of the NCI, which provides information on population-based cancer statistics. The dataset contains the following attributes: Table.1 Data Dictionary Attribute Description Patient ID Unique identification for each patient Month of Birth A patient’s month of birth Age A patient’s month of birth in years Sex A patient’s genomic sex Occupation The field of a patient’s job role T Stage The T stage in breast cancer refers to the size of the tumour from T1, T2, T3 and T4 N Stage Used to indicate if the breast cancer has spread to surrounding lymph nodes (N), with a higher number representing a greater number of lymph nodes impacted, from N1, N2 and N3. 6th Stage Breast Imaging Reporting and Data System or BI-RADS Differentiated How the cancer cells look and are growing compared with normal cells.
Grade Breast Cancer Grades (Nottingham Grading System) A Stage Breast cancer is staged based on how far it has spread.
Regional: The cancer has spread to nearby lymph nodes or tissues. Distant: The cancer has spread to distant parts of the body, such as the lungs, liver, or bones Tumour Size Tumor size measured in millimeters Estrogen Status Cancer cells have estrogen hormone receptors or not.
Progesterone Status Cancer cells have progesterone hormone receptors or not. Regional Node Examined Count of examined regional lymph nodes for cancer spread Regional Node Positive Count of cancer positive regional lymph nodes to contain metastases Survival Months Survival months based on date of last contact. Mortality Status Any patient that dies after the follow-up cut-off date is recoded to alive as of the cut-off date. If date of last contact > study cutoff date, vital status recoded = alive. Note: For general knowledge, further information about the collection of patients’ data can be found at https://ieee-dataport.org/open-access/seer-breast-cancer-data M. A. Aldraimli 5DATA002W.2 2024/2025 The survival calculations can be found at
https://seer.cancer.gov/survivaltime/ https://seer.cancer.gov/survivaltime/SurvivalTimeCalculation.pdf

This dataset of breast cancer patients was obtained from the 2017 November update of the SEER Program of the NCI, which provides information on population-based cancer statistics. The dataset involved female patients with infiltrating duct and lobular carcinoma breast cancer (SEER primary cites recode NOS histology codes 8522/3) diagnosed in 2006-2010. Patients with unknown tumour size, examined regional LNs, positive regional LNs, and patients whose survival months were less than 1 month were excluded; thus, 4024 patients were ultimately included.

Source: SEER (http://seer.cancer.gov/).aCancer of the corpus uteri or uterus, not otherwise specified.

Dataset

This dataset was created by MansiGambhir_13

Contents

Flat file of United States County-level cancer incidence rates obtained from: https://www.statecancerprofiles.cancer.gov/incidencerates/ All data housed on that website are extracts from the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) program with rates computed using SEER*Stat as documented in the About section of the above website.

This dataset contains Cancer Incidence data for Breast Cancer (All Stages^) including: Age-Adjusted Rate, Confidence Interval, Average Annual Count, and Trend field information for US States for the average 5 year span from 2016 to 2020.Data are for females segmented by age (All Ages, Ages Under 50, Ages 50 & Over, Ages Under 65, and Ages 65 & Over), with field names and aliases describing the sex and age group tabulated.For more information, visit statecancerprofiles.cancer.govData NotationsState Cancer Registries may provide more current or more local data.TrendRising when 95% confidence interval of average annual percent change is above 0.Stable when 95% confidence interval of average annual percent change includes 0.Falling when 95% confidence interval of average annual percent change is below 0.† Incidence rates (cases per 100,000 population per year) are age-adjusted to the 2000 US standard population (19 age groups: <1, 1-4, 5-9, ... , 80-84, 85+). Rates are for invasive cancer only (except for bladder cancer which is invasive and in situ) or unless otherwise specified. Rates calculated using SEER*Stat. Population counts for denominators are based on Census populations as modified by NCI. The US Population Data File is used for SEER and NPCR incidence rates.‡ Incidence Trend data come from different sources. Due to different years of data availability, most of the trends are AAPCs based on APCs but some are APCs calculated in SEER*Stat. Please refer to the source for each area for additional information.Rates and trends are computed using different standards for malignancy. For more information see malignant.^ All Stages refers to any stage in the Surveillance, Epidemiology, and End Results (SEER) summary stage.Data Source Field Key(1) Source: National Program of Cancer Registries and Surveillance, Epidemiology, and End Results SEER*Stat Database - United States Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute. Based on the 2022 submission.(5) Source: National Program of Cancer Registries and Surveillance, Epidemiology, and End Results SEER*Stat Database - United States Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute. Based on the 2022 submission.(6) Source: National Program of Cancer Registries SEER*Stat Database - United States Department of Health and Human Services, Centers for Disease Control and Prevention (based on the 2022 submission).(7) Source: SEER November 2022 submission.(8) Source: Incidence data provided by the SEER Program. AAPCs are calculated by the Joinpoint Regression Program and are based on APCs. Data are age-adjusted to the 2000 US standard population (19 age groups: <1, 1-4, 5-9, ... , 80-84,85+). Rates are for invasive cancer only (except for bladder cancer which is invasive and in situ) or unless otherwise specified. Population counts for denominators are based on Census populations as modified by NCI. The US Population Data File is used with SEER November 2022 data.Some data are not available, see Data Not Available for combinations of geography, cancer site, age, and race/ethnicity.Data for the United States does not include data from Nevada.Data for the United States does not include Puerto Rico.

Data from National Cancer instituted, better described at https://seer.cancer.gov/popdata/download.html

This data is adjusted such that Hurricane Katrina displaced victims in 2005 have their own cfips code.

Selected statistics describing the agreement between the two donor records across the 100 repetitions of the SEER cancer registry data for each of the six behaviours.

This datasets were extracted from the SEER Oncotype DX Database. Data clearing process was presented as a supplementary figure of the manuscript. (File format : SPSS 20.0 data file)

This dataset tracks the updates made on the dataset "Cancer Incidence - Surveillance, Epidemiology, and End Results (SEER) Registries Limited-Use" as a repository for previous versions of the data and metadata.

A nice clean panel of basic demographic information for every US county from 1969 to 2023. Variables include total population, percent white, percent black, percent male, percent children (age 0-17), and percent seniors (age 65+). This is a cleaned and reshaped version of the CDC SEER data available here: https://seer.cancer.gov/popdata/download.html

This dataset contains Cancer Incidence data for Colorectal Cancer (All Stages^) including: Age-Adjusted Rate, Confidence Interval, Average Annual Count, and Trend field information for US States for the average 5 year span from 2016 to 2020.Data are segmented by sex (Both Sexes, Male, and Female) and age (All Ages, Ages Under 50, Ages 50 & Over, Ages Under 65, and Ages 65 & Over), with field names and aliases describing the sex and age group tabulated.For more information, visit statecancerprofiles.cancer.govData NotationsState Cancer Registries may provide more current or more local data.TrendRising when 95% confidence interval of average annual percent change is above 0.Stable when 95% confidence interval of average annual percent change includes 0.Falling when 95% confidence interval of average annual percent change is below 0.† Incidence rates (cases per 100,000 population per year) are age-adjusted to the 2000 US standard population (19 age groups: <1, 1-4, 5-9, ... , 80-84, 85+). Rates are for invasive cancer only (except for bladder cancer which is invasive and in situ) or unless otherwise specified. Rates calculated using SEER*Stat. Population counts for denominators are based on Census populations as modified by NCI. The US Population Data File is used for SEER and NPCR incidence rates.‡ Incidence Trend data come from different sources. Due to different years of data availability, most of the trends are AAPCs based on APCs but some are APCs calculated in SEER*Stat. Please refer to the source for each area for additional information.Rates and trends are computed using different standards for malignancy. For more information see malignant.^ All Stages refers to any stage in the Surveillance, Epidemiology, and End Results (SEER) summary stage.Data Source Field Key(1) Source: National Program of Cancer Registries and Surveillance, Epidemiology, and End Results SEER*Stat Database - United States Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute. Based on the 2022 submission.(5) Source: National Program of Cancer Registries and Surveillance, Epidemiology, and End Results SEER*Stat Database - United States Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute. Based on the 2022 submission.(6) Source: National Program of Cancer Registries SEER*Stat Database - United States Department of Health and Human Services, Centers for Disease Control and Prevention (based on the 2022 submission).(7) Source: SEER November 2022 submission.(8) Source: Incidence data provided by the SEER Program. AAPCs are calculated by the Joinpoint Regression Program and are based on APCs. Data are age-adjusted to the 2000 US standard population (19 age groups: <1, 1-4, 5-9, ... , 80-84,85+). Rates are for invasive cancer only (except for bladder cancer which is invasive and in situ) or unless otherwise specified. Population counts for denominators are based on Census populations as modified by NCI. The US Population Data File is used with SEER November 2022 data.Some data are not available, see Data Not Available for combinations of geography, cancer site, age, and race/ethnicity.Data for the United States does not include data from Nevada.Data for the United States does not include Puerto Rico.

NA- not assessed/availablelcSSc- limited cutaneous systemic sclerosisdcSSc- diffuse cutaneous systemic sclerosisSSc/PPM- Systemic sclerosis and polymyositis overlapACA- anticentromere antibodySCL-70- anti-SCL 70 antibodyRNA Pol- anti-RNA polymerase III antibody* SCL-70 not assessedDemographics, smoking history and SSc subtype and serology.

Note: DPH is updating and streamlining the COVID-19 cases, deaths, and testing data. As of 6/27/2022, the data will be published in four tables instead of twelve.

The COVID-19 Cases, Deaths, and Tests by Day dataset contains cases and test data by date of sample submission. The death data are by date of death. This dataset is updated daily and contains information back to the beginning of the pandemic. The data can be found at https://data.ct.gov/Health-and-Human-Services/COVID-19-Cases-Deaths-and-Tests-by-Day/g9vi-2ahj.

The COVID-19 State Metrics dataset contains over 93 columns of data. This dataset is updated daily and currently contains information starting June 21, 2022 to the present. The data can be found at https://data.ct.gov/Health-and-Human-Services/COVID-19-State-Level-Data/qmgw-5kp6 .

The COVID-19 County Metrics dataset contains 25 columns of data. This dataset is updated daily and currently contains information starting June 16, 2022 to the present. The data can be found at https://data.ct.gov/Health-and-Human-Services/COVID-19-County-Level-Data/ujiq-dy22 .

The COVID-19 Town Metrics dataset contains 16 columns of data. This dataset is updated daily and currently contains information starting June 16, 2022 to the present. The data can be found at https://data.ct.gov/Health-and-Human-Services/COVID-19-Town-Level-Data/icxw-cada . To protect confidentiality, if a town has fewer than 5 cases or positive NAAT tests over the past 7 days, those data will be suppressed.

COVID-19 cases and associated deaths that have been reported among Connecticut residents, broken down by race and ethnicity. All data in this report are preliminary; data for previous dates will be updated as new reports are received and data errors are corrected. Deaths reported to the either the Office of the Chief Medical Examiner (OCME) or Department of Public Health (DPH) are included in the COVID-19 update.

The following data show the number of COVID-19 cases and associated deaths per 100,000 population by race and ethnicity. Crude rates represent the total cases or deaths per 100,000 people. Age-adjusted rates consider the age of the person at diagnosis or death when estimating the rate and use a standardized population to provide a fair comparison between population groups with different age distributions. Age-adjustment is important in Connecticut as the median age of among the non-Hispanic white population is 47 years, whereas it is 34 years among non-Hispanic blacks, and 29 years among Hispanics. Because most non-Hispanic white residents who died were over 75 years of age, the age-adjusted rates are lower than the unadjusted rates. In contrast, Hispanic residents who died tend to be younger than 75 years of age which results in higher age-adjusted rates.

The population data used to calculate rates is based on the CT DPH population statistics for 2019, which is available online here: https://portal.ct.gov/DPH/Health-Information-Systems--Reporting/Population/Population-Statistics. Prior to 5/10/2021, the population estimates from 2018 were used.

Rates are standardized to the 2000 US Millions Standard population (data available here: https://seer.cancer.gov/stdpopulations/). Standardization was done using 19 age groups (0, 1-4, 5-9, 10-14, ..., 80-84, 85 years and older). More information about direct standardization for age adjustment is available here: https://www.cdc.gov/nchs/data/statnt/statnt06rv.pdf

Categories are mutually exclusive. The category “multiracial” includes people who answered ‘yes’ to more than one race category. Counts may not add up to total case counts as data on race and ethnicity may be missing. Age adjusted rates calculated only for groups with more than 20 deaths. Abbreviation: NH=Non-Hispanic.

Data on Connecticut deaths were obtained from the Connecticut Deaths Registry maintained by the DPH Office of Vital Records. Cause of death was determined by a death certifier (e.g., physician, APRN, medical

Splitgraph serves as an HTTP API that lets you run SQL queries directly on this data to power Web applications. For example:

See the Splitgraph documentation for more information.

Cancer incidence is rising among adolescents (“teens”). The causes of the increase are unknown but studying incidence patterns and trends may produce insights into etiology. Using data from the US National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) program we described trends of cancer incidence among teens (15–19 year olds). We reviewed and summarized incidence patterns for histologic cancer groups and the most frequently diagnosed sites of cancer among teens during 2008–2012 reported by the SEER Cancer Statistics Review. We calculated annual incidence rates for the years 1975–2012 and used linear regression analysis to evaluate trends and calculate rates of change. Incidence for all sites combined increased annually by 0.67% for males and 0.62% for females during the period 1975 through 2012 –resulting in more than a 25% increase over 38 years. The biggest annual incidence increases occurred in non-Hodgkin lymphoma (NHL) (2.16% females; 1.38% males), thyroid cancer (2.12% females; 1.59% males), acute myeloid leukemia (AML) (1.73% females) and testicular cancer (1.55% males). Incidence rates for most histologic groups and sites showed steady long term increases over the 38 years of data. Despite improvements in survival, rising incidence trends mean growing numbers of young adults are undergoing painful and costly cancer treatments. A concerted research program is vital to investigate causes of steadily rising teen cancer rates.

Do you know further standard populations?

If you know any further standard populations worth integrating in this dataset, please let me know in the discussion part. I would be happy to integrate further data to make this dataset more useful for everybody.

German "Federal Health Monitoring System" about 'standard populations':

"Standard populations are "artificial populations" with fictitious age structures, that are used in age standardization as uniform basis for the calculation of comparable measures for the respective reference population(s).

Use: Age standardizations based on a standard population are often used at cancer registries to compare morbidity or mortality rates. If there are different age structures in populations of different regions or in a population in one region over time, the comparability of their mortality or morbidity rates is only limited. For interregional or inter-temporal comparisons, therefore, an age standardization is necessary. For this purpose the age structure of a reference population, the so-called standard population, is assumed for the study population. The age specific mortality or morbidity rates of the study population are weighted according to the age structure of the standard population. Selection of a standard population:

Which standard population is used for comparison basically, does not matter. It is important, however, that

1. the demographic structure of the standard population is not too dissimilar to that of the reference population and
2. the comparable rates refer to the same standard."

Aim of this dataset

The aim of this dataset is to provide a variety of the most commonly used 'standard populations'.

Currently, two files with 22 standard populations are provided: - standard_populations_20_age_groups.csv - 20 age groups: '0', '01-04', '05-09', '10-14', '15-19', '20-24', '25-29', '30-34', '35-39', '40-44', '45-49', '50-54', '55-59', '60-64', '65-69', '70-74', '75-79', '80-84', '85-89', '90+' - 7 standard populations: 'Standard population Germany 2011', 'Standard population Germany 1987', 'Standard population of Europe 2013', 'Standard population Old Laender 1987', 'Standard population New Laender 1987', 'New standard population of Europe', 'World standard population' - source: German Federal Health Monitoring System

• standard_populations_19_age_groups.csv
  • 19 age groups: '0', '01-04', '05-09', '10-14', '15-19', '20-24', '25-29', '30-34', '35-39', '40-44', '45-49', '50-54', '55-59', '60-64', '65-69', '70-74', '75-79', '80-84', '85+'
  • 15 standard populations: '1940 U.S. Std Million', '1950 U.S. Std Million', '1960 U.S. Std Million', '1970 U.S. Std Million', '1980 U.S. Std Million', '1990 U.S. Std Million', '1991 Canadian Std Million', '1996 Canadian Std Million', '2000 U.S. Std Million', '2000 U.S. Std Population (Census P25-1130)', '2011 Canadian Standard Population', 'European (EU-27 plus EFTA 2011-2030) Std Million', 'European (Scandinavian 1960) Std Million', 'World (Segi 1960) Std Million', 'World (WHO 2000-2025) Std Million'
  • source: National Institutes of Health, National Cancer Institute, Surveillance, Epidemiology, and End Results Program

Terms of use

No restrictions are known to the author. Standard populations are published by different organisations for public usage.